Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib cardiac repolarization study in healthy subjects
NCT03777761Phase 1Completed
- Sponsor
- Seagen Inc.
- Start
- Dec 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tucatinib in breast cancer (6 arms), sponsored by Seagen Inc. Primary endpoint: Placebo-corrected change-from-baseline in QTcF up to 32 days. Started Dec 2018; status: completed.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03777761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777761.